Alteplase as an Adjunct to Primary PCI | JACC | TCT 2025

JACC continues its partnership with TCT 2025 in our latest interview, featuring JACC: Associate Editor Yousif Ahmad, MBBS, PhD, and author Shamir R. Mehta, MD, MSc. Listen here as they discuss this randomized, double-blind trial presented at TCT 2025 and published in JACC. Mehta et al demonstrate that intracoronary low-dose alteplase did not improve outcomes in STEMI patients with large thrombus burden and may increase arrhythmic risk. Together with prior studies, STRIVE closes the chapter on adjunctive intracoronary fibrinolysis as a strategy to improve outcomes during primary PCI.